PRRT2 and cancer: The discovery of PKC activation by tumor-promoting agent phorbol 12-myristate 13-acetate (PMA) in 1982 [28] drew attention to this family of kinases based on the plethora of cell biologic responses to PMA and other phorbol esters, warranting extensive research that implicated PKC isozymes in various pathologies, including cancer, heart disease, diabetes, and several neurological diseases [10,11,12,13,14,15,16].